GLP Weight Loss
Tirzepatide vs Semaglutide for Clinic Weight Loss Programs
A practical comparison of dual GIP/GLP-1 and GLP-1-only pathways to help clinics align formulary choices with patient profiles.
Master Pharm Professional Services TeamJune 18, 20267 min read
Clinics expanding metabolic health services often evaluate both Semaglutide (GLP-1 agonist) and Tirzepatide (dual GIP/GLP-1 agonist). Understanding pathway differences helps teams design tiered formulary options and match compounds to program goals.
Pathway Overview
- Semaglutide: GLP-1 receptor agonism for appetite and glycemic modulation
- Tirzepatide: Dual GIP and GLP-1 activity for complementary metabolic signaling
- Both require structured titration and clinical oversight
Formulary Strategy for Growing Practices
Many clinics maintain both compounds to support protocol flexibility — introductory GLP-1 pathways, advanced dual-incretin programs, and patient-specific transitions under physician direction. Consistent supply partners simplify inventory forecasting across SKUs.
